Back to search results

Long-term Health for Medulloblastoma Survivors After Craniospinal Irradiation

This study, called CSIMEMPHIS, is looking at the long-term health of people who had medulloblastoma (a type of brain tumor) and were treated with radiation therapy (craniospinal irradiation) at St. Jude Children's Research Hospital. The goal is to understand how different radiation doses and chemotherapy treatments affect survivors over time. Researchers want to identify lasting health problems, like memory issues, hearing loss, or heart problems, that might come from their past treatments. This information will help improve care for future medulloblastoma survivors. You may be able to join if you were diagnosed with medulloblastoma between ages 3-22 (or 22-44 for a specific subtype) and received radiation therapy at St. Jude at least five years ago.

Study design
This is an observational study, meaning researchers will watch and collect information without giving new treatments. It plans to include 184 participants.
What's involved
You will be invited to enroll in this study and the St. Jude Lifetime Cohort (SJLIFE) protocol. You and your parents/guardians will also complete surveys about your health.
Compensation
Not stated in the trial record.
Follow-up
This study will evaluate health outcomes at a baseline timepoint, serving as the start for future follow-up.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07085325

CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation

Recruiting
Not specifiedAll AgesObservational
St. Jude Children's Research Hospital
~184 participants
Updated 2026-07-06 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To describe and compare the long-term health outcomes among medulloblastoma survivors treated with radiation therapy on or according to the SJMB12 protocol with varying craniospinal doses, chemotherapy regimens, and radiation modalities.
Measured over Baseline

Conditions

Medulloblastoma

Explore related trials

MedulloblastomaSonic Hedgehog Protein

NCT07085325

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • St. Jude Children's Research Hospital

    Memphis, Tennesseestudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Thomas E Merchant, DO, PhD · PRINCIPAL_INVESTIGATOR · St. Jude Children's Research Hospital

Who to contact

Thomas E Merchant, DO, PhD
[email protected]
888-226-4343
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of any subtype of medulloblastoma between the ages of 3 to 22 years or between the ages of 22 to 44 years with the sonic hedgehog (SHH) subtype of medulloblastoma
Radiotherapy on or according to the SJMB12 protocol
Received radiotherapy at St. Jude Children's Research Hospital
5 or more years since the initiation of radiation therapy and who did not have evidence of disease progression
Provision of informed consent by participant/guardian or legal representative; Assent by minor participant
Participants may choose to complete all or a subset of the proposed assessments; refusal to participate in some aspects of the study will not preclude participant inclusion
Participants must also complete enrollment on SJLIFE

Exclusion

Participants or their legal guardian/representative are unwilling or unable to provide written informed consent.
Participants who had relapsed or refractory disease during or following completion of treatment for medulloblastoma

What this trial measures

  • To describe and compare the long-term health outcomes among medulloblastoma survivors treated with radiation therapy on or according to the SJMB12 protocol with varying craniospinal doses, chemotherapy regimens, and radiation modalities.Baseline

    In the SJLIFE study Survivors will undergo the SJLIFE core battery of testing with a focus on outcomes for which early evidence has demonstrated the potential association between proton therapy and reduced late-effect burden. Testing includes neuromuscular function, laboratory testing, neurocognitive assessments, physiologic assessments, and outcome questionnaires.